Insmed Incorporated (NASDAQ:INSM) went down by -3.49% from its latest closing price compared to the recent 1-year high of $45.44. The company’s stock price has collected -12.02% of loss in the last five trading sessions. Press Release reported on 01/04/22 that Insmed To Present at the 40th Annual J.P. Morgan Healthcare Conference
Is It Worth Investing in Insmed Incorporated (NASDAQ :INSM) Right Now?
Plus, the 36-month beta value for INSM is at 2.16. Opinions of the stock are interesting as 10 analysts out of 10 who provided ratings for Insmed Incorporated declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $52.60, which is $28.52 above the current price. INSM currently public float of 116.65M and currently shorts hold a 6.35% ratio of that float. Today, the average trading volume of INSM was 749.16K shares.
INSM’s Market Performance
INSM stocks went down by -12.02% for the week, with a monthly drop of -6.82% and a quarterly performance of -16.13%, while its annual performance rate touched -32.65%. The volatility ratio for the week stands at 6.15% while the volatility levels for the past 30 days are set at 5.17% for Insmed Incorporated. The simple moving average for the period of the last 20 days is -9.81% for INSM stocks with a simple moving average of -12.76% for the last 200 days.
Analysts’ Opinion of INSM
Many brokerage firms have already submitted their reports for INSM stocks, with JP Morgan repeating the rating for INSM by listing it as a “Overweight.” The predicted price for INSM in the upcoming period, according to JP Morgan is $45 based on the research report published on December 06th of the previous year 2021.
Morgan Stanley, on the other hand, stated in their research note that they expect to see INSM reach a price target of $52, previously predicting the price at $56. The rating they have provided for INSM stocks is “Overweight” according to the report published on October 19th, 2021.
Monness Crespi & Hardt gave a rating of “Buy” to INSM, setting the target price at $52 in the report published on October 19th of the previous year.
INSM Trading at -14.65% from the 50-Day Moving Average
After a stumble in the market that brought INSM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.88% of loss for the given period.
Volatility was left at 5.17%, however, over the last 30 days, the volatility rate increased by 6.15%, as shares sank -8.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.44% lower at present.
During the last 5 trading sessions, INSM fell by -12.02%, which changed the moving average for the period of 200-days by -24.43% in comparison to the 20-day moving average, which settled at $27.15. In addition, Insmed Incorporated saw -9.73% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at INSM starting from Adsett Roger, who sale 1,759 shares at the price of $26.00 back on Jan 06. After this action, Adsett Roger now owns 105,420 shares of Insmed Incorporated, valued at $45,734 using the latest closing price.
Lewis William, the Chair and CEO of Insmed Incorporated, sale 5,337 shares at $26.00 during a trade that took place back on Jan 06, which means that Lewis William is holding 189,756 shares at $138,762 based on the most recent closing price.
Stock Fundamentals for INSM
Current profitability levels for the company are sitting at:
- -161.32 for the present operating margin
- +72.71 for the gross margin
The net margin for Insmed Incorporated stands at -178.87. The total capital return value is set at -39.60, while invested capital returns managed to touch -44.74. Equity return is now at value -112.00, with -42.10 for asset returns.
Based on Insmed Incorporated (INSM), the company’s capital structure generated 146.74 points at debt to equity in total, while total debt to capital is 59.47. Total debt to assets is 50.85, with long-term debt to equity ratio resting at 142.19. Finally, the long-term debt to capital ratio is 57.63.
When we switch over and look at the enterprise to sales, we see a ratio of 16.62, with the company’s debt to enterprise value settled at 0.13. The receivables turnover for the company is 9.19 and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.24.